Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
SKIN vs FIGS: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
FIGS Wins Head-to-Head Institutional Verdict (5–1 across 6 Pillars · 9–0 Matrix Metrics)
FIGS Overall Winner
6-Pillar Tally: SKIN 1 – 5 FIGS
Matrix Metrics: SKIN 0 – 9 FIGS
As of Nov 16, 2026, FIGS, Inc. (FIGS) is the stronger overall head-to-head candidate over The Beauty Health Company (SKIN) in the Tradestie Institutional Equity Comparison Engine, winning 9–0 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). SKIN carries a Unified Composite Score of 34.1/100 (SELL) at $15.05 (106.4x Forward P/E, 2.4% operating margin), whereas FIGS carries 43.7/100 (HOLD) at $21.34 (49.2x Forward P/E, 9.7% operating margin).
Executive Snapshot Side-by-Side Composite Ratings & Technical Regime
Ask Alpha AI About SKIN vs FIGS
SKIN
The Beauty Health Company Class A Common Stock
$15.05
-7.73% 1D
Market Cap
$106.3M
TTM Revenue
$289M
Forward P/E
106.4x
Beta / 30D Vol
-14.22β · 192% Vol
Unified Composite Score
34.1
SELL
Tech 50.0
Fund 34.0
Flow 67.0
Mom 46.0
Weinstein Technical Phase
Markup · Hold / add on dips
FIGS
Head-to-Head Winner
FIGS, Inc.
$21.34
-3.22% 1D
Market Cap
$3.7B
TTM Revenue
$749M
Forward P/E
49.2x
Beta / 30D Vol
1.10β · 59% Vol
Unified Composite Score
43.7
HOLD
Tech 30.0
Fund 35.0
Flow 68.0
Mom 1.1
Weinstein Technical Phase
Markup · Hold / add on dips
6-Pillar Scorecard Institutional Category Breakdown (SKIN 1 – 5 FIGS)
1. Valuation Multiples
FIGS
Forward P/E
106.4x
49.2x
Trailing P/E
106.4x
58.0x
PEG Ratio
0.93x
N/M
EV / Revenue
0.9x
4.9x
2. Growth & Scale
FIGS
Revenue Growth (YoY)
-2.1%
+25.7%
Earnings Growth (YoY)
+0.0%
+100.0%
TTM Revenue (USD)
$289M
$749M
Market Cap
$106.3M
$3.7B
3. Profitability & Quality
FIGS
Gross Margin
67.2%
67.7%
Operating Margin
2.4%
9.7%
Net Profit Margin
-6.3%
9.7%
Return on Equity (ROE)
-30.1%
16.8%
4. Balance Sheet & Cash Flow
FIGS
Cash Generation (TTM)
$17M
$148M
Cash Flow Margin
5.8%
19.7%
Net Cash / Leverage
$161M Net Debt (6.61x D/E)
$9.5M Net Cash
Dividend Yield
None (0.00%)
None (0.00%)
5. Options & Positioning
FIGS
Options Structure Phase
UNCLASSIFIED
BREAKOUT
Current IV / %ile
517.4% (100th %ile)
77.0% (38th %ile)
Put/Call OI Skew
N/A
0.14x (Call-Skewed)
OBV Trend / Tech Phase
NEUTRAL · Markup
NEUTRAL · Markup
6. R&D & Supply-Chain Moat
SKIN
OpEx & R&D Intensity
64.8% of Rev ($187M)
58.0% of Rev ($434M)
90D R&D Disclosures
0 papers
0 papers
Competitive Moat
Cyclical / Execution-Driven Positioning
Cyclical / Execution-Driven Positioning
Supply-Chain Role
Household & Personal Products Operator
Apparel Manufacturing Operator
Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table
Core Matrix Wins: SKIN (0) vs FIGS (9)| Institutional Metric | SKIN | FIGS | Criterion | Row Edge |
|---|---|---|---|---|
| Market Capitalization | $106.3M | $3.7B | FIGS | |
| Trailing P/E Ratio | 106.4x | 58.0x | FIGS | |
| Forward P/E Ratio | 106.4x | 49.2x | FIGS | |
| Revenue Growth (YoY) | -2.1% | +25.7% | FIGS | |
| Operating Margin (TTM) | 2.4% | 9.7% | FIGS | |
| Net Profit Margin | -6.3% | 9.7% | FIGS | |
| Return on Equity (ROE) | -30.1% | 16.8% | FIGS | |
| 52-Week Range Position | 83% ($0–$18) | 84% ($9–$24) | Tie | |
| Beta / 30D Volatility | -14.22β · 192% Vol | 1.10β · 59% Vol | FIGS | |
| Unified Institutional Score | 34.1 / 100 (SELL) | 43.7 / 100 (HOLD) | FIGS | |
| Trailing 12M Revenue (USD) | $289M | $749M | Scale | |
| Gross Profit Margin (TTM) | 67.2% | 67.7% | Quality | |
| PEG Ratio & EV / Revenue | 0.93x PEG · 0.9x EV/Rev | N/M PEG · 4.9x EV/Rev | Valuation | |
| Cash Flow & Balance Sheet | $17M ($161M Net Debt (6.61x D/E)) | $148M ($9.5M Net Cash) | Solvency |
Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)
1M Horizon
SKIN +30.91 pp
3M Horizon
SKIN +2357.62 pp
6M Horizon
SKIN +2299.57 pp
1Y Horizon
SKIN +930.67 pp
Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | SKIN Revenue | FIGS Revenue | SKIN Op. Margin | FIGS Op. Margin | Margin Leader |
|---|---|---|---|---|---|
| FY2019 | $170M | $110M | 8.1% | -0.3% | SKIN |
| FY2020 | $120M | $260M | -14.4% | 22.0% | FIGS |
| FY2021 | $260M | $420M | -15.4% | 2.6% | FIGS |
| FY2022 | $370M | $510M | -7.1% | 7.4% | FIGS |
| FY2023 | $400M | $550M | -32.9% | 6.2% | FIGS |
| FY2024 | $330M | $560M | -20.3% | 0.4% | FIGS |
| FY2025 | $300M | $630M | -6.9% | 6.0% | FIGS |
Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor
Live Options Phase Tracker
SKIN
UNCLASSIFIED
Current IV
517.4%
IV Percentile
100th %ile
Put/Call OI Skew
N/A
IV Regime
Extreme (>80th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BEARISH
OBV Flow
NEUTRAL
Exact SKIN Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
FIGS
BREAKOUT
Current IV
77.0%
IV Percentile
38th %ile
Put/Call OI Skew
0.14x (Call-Skewed)
IV Regime
Balanced (25th–60th %ile)
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
Net Delta Signal
BULLISH
OBV Flow
NEUTRAL
Exact FIGS Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro.
Unlock 14-Day Free Trial →
Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity
Corporate R&D & Foundry Leaderboard
SKIN Moat Profile
Cyclical / Execution-Driven Positioning
Household & Personal Products Operator
OpEx & R&D Reinvestment
64.8% of Rev ($187M)
90D Engineering Disclosures
0 Published
FIGS Moat Profile
Cyclical / Execution-Driven Positioning
Apparel Manufacturing Operator
OpEx & R&D Reinvestment
58.0% of Rev ($434M)
90D Engineering Disclosures
0 Published
Investor FAQ SKIN vs FIGS Key Questions & Quantitative Answers
As of Nov 16, 2026, FIGS, Inc. (FIGS) is the stronger overall head-to-head candidate over The Beauty Health Company (SKIN) in the Tradestie Institutional Equity Comparison Engine, winning 9–0 core matrix metrics and 5–1 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). SKIN carries a Unified Composite Score of 34.1/100 (SELL) at $15.05 (106.4x Forward P/E, 2.4% operating margin), whereas FIGS carries 43.7/100 (HOLD) at $21.34 (49.2x Forward P/E, 9.7% operating margin). Technically, SKIN sits in a Markup phase (RSI 69.8, UNCLASSIFIED options structure) and FIGS sits in a Markup phase (RSI 58.4, BREAKOUT options structure).
FIGS leads the Growth & Scale pillar: SKIN posts -2.1% YoY revenue growth and +0.0% YoY earnings growth on $289M TTM revenue (67.2% gross margin, 2.4% operating margin), compared with FIGS at +25.7% YoY revenue growth and +100.0% YoY earnings growth on $749M TTM revenue (67.7% gross margin, 9.7% operating margin). Across the 7-period historical trajectory (FY2019 to FY2025), SKIN cumulative revenue shifted +76.5% while FIGS shifted +472.7%. In operating R&D and SG&A reinvestment, SKIN deploys 64.8% of Rev ($187M) (0 90-day corporate R&D disclosures) versus 58.0% of Rev ($434M) (0 disclosures) for FIGS.
FIGS screens cheaper on headline valuation multiples. SKIN trades at 106.4x Forward P/E, 106.4x Trailing P/E, 0.93x PEG, and 0.9x EV/Revenue (5.8% FCF margin), whereas FIGS trades at 49.2x Forward P/E, 58.0x Trailing P/E, N/M PEG, and 4.9x EV/Revenue (19.7% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SKIN (-30.1% ROE) versus FIGS (16.8% ROE) capital efficiency.
In options market volatility and institutional positioning, SKIN carries 517.4% implied volatility (100th %ile, Extreme (>80th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (-14.22β · 192% Vol realized risk). By comparison, FIGS carries 77.0% implied volatility (38th %ile, Balanced (25th–60th %ile)), a 0.14x (Call-Skewed) Put/Call open-interest ratio, NEUTRAL on-balance volume, and sits in a BREAKOUT options structure phase (1.10β · 59% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Launch Custom Ticker Comparison →
FIGS vs SKIN · Reverse Pair
SKIN vs MRVI
· Sector Peer
SKIN vs PRCH
· Sector Peer
FIGS vs DOCS
· Sector Peer
FIGS vs YOU
· Sector Peer
FIGS vs MQ
· Sector Peer
INTC vs AMD
· x86 & Data Center CPU
NVDA vs AMD
· AI Accelerators
TSM vs ASML
· Foundry & Lithography
MSFT vs GOOGL
· Hyperscale Cloud & AI
AAPL vs META
· Consumer Ecosystem